Glen Clova Scientific is developing Active Biologic drugs that enable patients to generate natural antibodies against harmful targets, significantly reducing dosing frequency to 1-2 initial doses and 1-2 annual boosts. This approach addresses the limitations of conventional biologic drugs, including high costs and complex manufacturing, by utilizing a single cell bank for VLP scaffolds and a generic purification scheme that minimizes drug per dose and safety monitoring requirements.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional biologic drugs often require frequent dosing, extensive safety monitoring, complex manufacturing processes, and high drug volumes per dose, leading to high costs and limited market access. These limitations hinder the treatment of chronic diseases, particularly in regions with limited healthcare infrastructure.
Solution
Glen Clova Scientific is developing Active Biologic drugs that stimulate patients to generate their own natural antibodies against harmful targets, significantly reducing the required dosing frequency. Their approach involves an initial induction phase of one to two doses, followed by one to two annual booster shots. By utilizing a single cell bank for VLP scaffolds and a generic purification scheme, the company minimizes the amount of drug needed per dose and reduces the need for intensive safety monitoring, resulting in a more cost-effective and accessible treatment option.
Target Audience
The primary target audience includes patients with chronic diseases who are unable to access or afford conventional biologic drugs, as well as healthcare providers in regions with limited infrastructure.
Features
- Active Biologic drugs stimulate the patient's own immune system to produce antibodies.
- Reduced dosing frequency: 1-2 initial doses followed by 1-2 annual boosts.
- Low drug volume per dose (micrograms instead of milligrams).
- Simplified manufacturing process using a single cell bank for VLP scaffold and displayed protein.
- Generic purification scheme applicable to any displayed protein.
- Built-in chaperone for difficult-to-express proteins.
- No requirement for genetic fusion or covalent/chemical linkage of displayed protein.